OSU Harding Hospital and the OSU Department of Psychiatry are committed to finding new treatments to decrease morbidity and mortality and improve the quality of life of patients with mental and behavioral disorders.
The clinical trials program at OSU Harding Hospital and the OSU Department of Psychiatry is one way to determine whether new treatments are safe and effective. The Division of Clinical Trials has continued to expand its investigator-initiated and industry-sponsored research under Dr. Campo's leadership.
During the past year, we conducted clinical trials in the areas of anxiety, depression, ADHD, bipolar disorder and schizophrenia in adults and children/adolescents. Our Phase II and III clinical trials are exploring potential treatments from new classes of psychotropic drugs. In addition, the Department of Psychiatry is one of twenty sites worldwide involved in the I-SPOT-D protocol, an international study looking at markers of response to antidepressants to predict optimized treatment in depression.